exs21546
tetraphase pharmaceutical,exscientia,evotec
['exs21546', 'ignite,(-reignited),(-ignited)']
#aacr23: eric helmer, vp, head of early development presents poster ct114 confirming phase 1 safety and tolerability of exs21546, our a2ar-selective antagonist, and design of the ignite phase 1/2 patient study using continual reassessment method settings. 
Patient-first AI to discover better drugs, faster